These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride. Shibata Y; Fukabori Y; Ito K; Suzuki K; Yamanaka H J Urol; 2001 Jan; 165(1):289-93. PubMed ID: 11125427 [TBL] [Abstract][Full Text] [Related]
5. Benign hypertrophy of the prostate. Mogere RM; Baraza R East Afr Med J; 2007 Dec; 84(12):553-5. PubMed ID: 18402305 [No Abstract] [Full Text] [Related]
6. Pharmacological treatment of benign prostatic hyperplasia, current options and future perspectives. Hansen BJ Scand J Urol Nephrol Suppl; 1996; 180():1-55. PubMed ID: 8936639 [No Abstract] [Full Text] [Related]
7. [Indications of antiandrogens in benign hyperplasia of the prostate]. Benassayag E J Urol (Paris); 1995; 101(2):109-10. PubMed ID: 8522854 [No Abstract] [Full Text] [Related]
8. 4. Steroid pathophysiology of BPH. Correlative morphological and biochemical investigations on the stromal tissue of the human prostate. Bartsch G; Daxenbichler G; Rohr HP J Steroid Biochem; 1983 Jul; 19(1A):147-54. PubMed ID: 6193337 [TBL] [Abstract][Full Text] [Related]
9. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586 [TBL] [Abstract][Full Text] [Related]
14. [Results of the effectiveness of long-term treatment of patients with benign prostatic hyperplasia]. Tkachuk VN; Al'-Shukri SKh; Luk'ianov AE Urologiia; 2002; (2):11-3. PubMed ID: 12077812 [TBL] [Abstract][Full Text] [Related]
15. [Current drug therapy of benign prostatic hyperplasia]. Schmidbauer CP; Madersbacher S Wien Med Wochenschr; 1996; 146(8):161-4. PubMed ID: 8767400 [TBL] [Abstract][Full Text] [Related]
16. [Flutamide, an alternative for patients with benign prostatic hyperplasia (BPH) that cannot be treated with surgery]. Granados EA Arch Esp Urol; 1998 Sep; 51(7):675-9. PubMed ID: 9807893 [TBL] [Abstract][Full Text] [Related]
17. [The use of serpens for treating patients with benign prostatic hyperplasia]. Mazo EB; Chekhonin VP; Riabukhin IA; Grigor'ev ME Ter Arkh; 1996; 68(10):47-9. PubMed ID: 9026943 [TBL] [Abstract][Full Text] [Related]
18. [Androgen deprivation in benign prostatic hypertrophy]. Tenaglia R; Nicolai M; Di Federico G; Iantorno R; Zezza A; Lombardi G J Urol (Paris); 1993; 99(6):296-8. PubMed ID: 7516371 [TBL] [Abstract][Full Text] [Related]
19. [The course and limitation of medical treatment for benign prostatic hyperplasia]. Kitagawa N; Akakura K; Akimoto S; Shimazaki J; Murakami S; Ishikawa T; Kataumi S; Sotoma T; Takagishi H; Kitamura Y Hinyokika Kiyo; 1994 Sep; 40(9):781-8. PubMed ID: 7528462 [TBL] [Abstract][Full Text] [Related]
20. An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases. Evans CP; Fleshner N; Fitzpatrick JM; Zlotta AR BJU Int; 2005 Apr; 95(6):743-9. PubMed ID: 15794775 [No Abstract] [Full Text] [Related] [Next] [New Search]